NFA
GALT icon

Nationwide Fund Advisors’s Galectin Therapeutics GALT Stock Holding History

Nationwide Fund Advisors’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-14,142
Closed -$47K – 3322
2015
Q1 		$47K Hold
14,142
– – ﹤0.01% 3109
2014
Q4 		$49K Hold
14,142
– – ﹤0.01% 3024
2014
Q3 		$71K Buy
14,142
+376
+3% +$2.93K ﹤0.01% 3060
2014
Q2 		$190K Buy
+13,766
New +$171K ﹤0.01% 2778

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nationwide Fund Advisors's GALT Position: Q2 2015 in Review

Nationwide Fund Advisors sold out of Galectin Therapeutics (GALT) in Q2 2015, closing a stake of 14,142 shares — an estimated $47K sold.

Nationwide Fund Advisors first reported a position in GALT in Q2 2014 and held it in 4 quarters. The position peaked at $190K in Q2 2014. 58 funds tracked by Wall St. Rank hold GALT as of Q2 2015.

  • Nationwide Fund Advisors reported no remaining Galectin Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Nationwide Fund Advisors sold 14,142 Galectin Therapeutics shares in Q2 2015, an estimated $47K.
  • Nationwide Fund Advisors first reported a position in Galectin Therapeutics in Q2 2014 and held it in 4 quarters.
  • Nationwide Fund Advisors's Galectin Therapeutics position peaked at $190K in Q2 2014.
  • 58 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2015.

Based on Nationwide Fund Advisors's 13F filing for Q2 2015, filed 29 Jul 2015.